Leanne Ross

Statistics

Publications

Citations

458

H-Index

Active since

2011

Affiliations

Charles River Laboratories (United Kingdom)(Current)

Leanne Ross is an author at Charles River Laboratories (United Kingdom) specializing in pharmacology, molecular oncology, and oncogenic signaling pathways.

Publications per year

2011–2019

Publications

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Jeffrey J. Wallin, Kyle A. Edgar, Jane Guan et al. · Molecular Cancer Therapeutics · 2011 · 228 citations

Medicine, Oncology, Pharmacology +16

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

Jill M. Spoerke, Carol O’Brien, Ling Huw et al. · Clinical Cancer Research · 2012 · 179 citations · Full text

Medicine, Cancer Biology, Oncology +17

Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma

Xiaojing Wang, Wesley Blackaby, Vivienne Allen et al. · Journal of Medicinal Chemistry · 2019 · 36 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Abstract DDT02-01: Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors.

Alan G. Olivero, Timothy P. Heffron, Matthew Baumgardner et al. · Cancer Research · 2013 · 15 citations

Pharmacy, Oncology, Pharmacology +14

1–4 of 4